VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 9, 2007) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today reported its third quarter operating results. Highlights of this quarter include the continued advancement of the Company’s three Phase II human efficacy programs, with patient screening having been completed in the Phase II Alzheimer’s trial that is expected to report data in Q1 2008. Subsequent to the end of the quarter, the Company announced that enrollment was complete.
